For-L-Nle-L-Leu-L-Phe-OH | 61864-82-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: For-L-Nle-L-Leu-L-Phe-OH
• 英文别名: N-formyl-norleucine-leucine-phenylalanine；N-formyl-Nle-Leu-Phe；n-formyl-L-norleucyl-L-leucyl-L-phenylalanine；(2S)-2-[[(2S)-2-[[(2S)-2-formamidohexanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoic acid
• CAS: 61864-82-2
• 化学式: C₂₂H₃₃N₃O₅
• mdl: MFCD00057578
• 分子量: 419.521
• InChiKey: ZNPUQLFXFVLCID-FHWLQOOXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  30
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.545
• 拓扑面积：
  125
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  For-L-Nle-L-Leu-L-Phe-OH 、 N-Boc-4,7,10-三氧杂-1,13-十三烷二胺 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三异丙基硅烷 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 、 二氯甲烷 为溶剂， 反应 32.0h， 以73%的产率得到
  参考文献：
  名称：

  Unexpected Enhancement in Biological Activity of a GPCR Ligand Induced by an Oligoethylene Glycol Substituent

  摘要：

  Polyethylene glycol (PEG) is widely used, and many biologically active molecules are modified with oligoethylene glycol substituents to enhance their half-lives in circulation. The pervasive use of PEG substituents is partly due to their presumed inertness. Our investigation of formyl peptide receptor (FPR)-mediated chemotaxis reveals that oligoethylene glycol substitution can enhance the ability of the peptide chemoattractant N-formyl-methionine-leucine-phenylalanine (fMLF) to activate signal transduction through FPR, a transmembrane G-protein-coupled receptor.

  DOI：

  10.1021/ja102640c

文献信息

• Unique elastase induced fibrinogen cleavage site antigens
  申请人：Merck & Co., Inc.

  公开号：EP0345906A2

  公开（公告）日：1989-12-13

  Novel peptides associated with the amino and carboxyl termini of human leukocyte elastase cleavage sites of human fibrinogen are disclosed. The peptides are used to raise antibodies which are specific for as few as five amino acids on either side of the enzymatic cleavage site. The unique peptides are also used in novel assays for the rapid determination of in vivo and in vitro elastase cleavage products.

  本研究公开了与人类纤维蛋白原的人类白细胞弹性蛋白酶裂解位点的氨基和羧基末端相关的新型肽。这些肽可用于培养抗体，这种抗体对酶裂解位点两侧少至五个氨基酸具有特异性。这种独特的肽还可用于快速测定体内和体外弹性蛋白酶裂解产物的新型检测方法。
• Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities
  申请人：——

  公开号：US20040132820A1

  公开（公告）日：2004-07-08

  The present invention relates to the use of the antiviral activity of exogenous leukotriene B 4 (LTB 4 ), variants and derivatives thereof as a therapeutic agent in viral infections caused by human and animal viruses. The present invention also relates to the use of LTB 4 as an anti-neoplastic agent in the prophylaxis and treatment of cancers induced by tumor viruses and in other neoplasic diseases. The human and animal viruses are DNA viruses, such as parvoviridae, papovaviridae, adenoviridae, herpesviridae, poxyviridae and hepadnaviridae; RNA viruses, such as picornaviridae, togaviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, reoviridae, and filoviridae in general, and Retroviridae such as HIV-1 and HIV-2.

  本发明涉及利用外源性白三烯 B 4 (LTB 4 )、其变体和衍生物的抗病毒活性作为人类和动物病毒引起的病毒感染的治疗剂。本发明还涉及使用 LTB 4 作为抗肿瘤剂，用于预防和治疗由肿瘤病毒诱发的癌症和其他肿瘤性疾病。人类和动物病毒包括 DNA 病毒，如副病毒科、乳头瘤病毒科、腺病毒科、疱疹病毒科、poxyviridae 和 hepadnaviridae；RNA 病毒，如 picornaviridae、togaviridae、orthomyxoviridae、paramyxoviridae、coronaviridae、reoviridae 和 filoviridae，以及逆转录病毒科，如 HIV-1 和 HIV-2。
• In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
  申请人：Gosselin Jean

  公开号：US20050239889A1

  公开（公告）日：2005-10-27

  The invention relates to the in vivo release of endogenous anti-microbial mediators using leukotriene B4 administration. The present invention furthermore relates to the use of leukotriene B4 for the treatment and/or prophylaxis of diseases that are positively influenced by such anti-microbial mediators.

  本发明涉及使用白三烯 B4 在体内释放内源性抗微生物介质。本发明还涉及使用白三烯 B4 治疗和/或预防受此类抗微生物介质积极影响的疾病。
• Antagonist peptides to the C5A chemotactic function of vitamin D binding protein
  申请人：Kew R. Richard

  公开号：US20060094659A1

  公开（公告）日：2006-05-04

  It has been demonstrated that one of Vitamin D Binding Protein (DBP) biological functions is to enhance the chemotactic activity of C5a and C5a des Arg. The present invention has found that peptides having sequences that substantially correspond to a specific region in the N-terminal domain I of DBP can block the DBP enhancement of C5a or C5a des Arg chemotactic activity. Based in this discovery the present invention provides DBP antagonist peptides and the use thereof for the treatment C5a or C5a des Arg-mediated disorders.

  研究表明，维生素 D 结合蛋白（DBP）的生物功能之一是增强 C5a 和 C5a des Arg 的趋化活性。本发明发现，具有与 DBP 的 N 端结构域 I 中的特定区域基本对应的序列的多肽可以阻断 DBP 增强 C5a 或 C5a des Arg 趋化活性。基于这一发现，本发明提供了 DBP 拮抗剂肽及其在治疗 C5a 或 C5a des Arg 介导的疾病中的用途。
• Regioselective Postsynthetic Modification of Phenylalanine Side Chains of Peptides Leading to Uncommonortho-Iodinated Analogues
  作者：Gemma Espuña、Gemma Arsequell、Gregorio Valencia、José Barluenga、Julia M. Alvarez-Gutiérrez、Alfredo Ballesteros、José M. González

  DOI：10.1002/anie.200352464

  日期：2004.1.5